The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas
Published version of a preprint
Abstract
Purpose: This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratumoral injection of hafnium oxide nanoparticles (NBTXR3; a radioenhancer) and external beam radiotherapy (EBRT) for preoperative treatment of adults with locally advanced soft tissue sarcoma (STS). Experimental Design: Patients had a preoperative indication of EBRT for STS of the extremity or trunk. Baseline tumor volume (TV) was calculated by MRI. NBTXR3 was injected percutaneously into tumors at 53.3 g/L. Dose escalation was based on four levels equivalent to 2.5%, 5%, 10%, and 20% of baseline TV. NBTXR3 was visualized in the tumor 24 hours postinjection, and EBRT was initiated (50 Gy over 5 weeks). Surgery was performed 6 to 8 weeks after EBRT completion. Results: Twenty-two patients completed NBTXR3 injection, EBRT, and surgery and were followed for a median 22 months (range, 6–40). At NBTXR3 20% of TV, two dose-limiting toxicities occurred: injection-site pain and postoperative scar necrosis. The RD was defined as 10%. No leakage of NBTXR3 into surrounding tissues occurred; intratumor NBTXR3 levels were maintained during radiotherapy. At the RD, median tumor shrinkage was 40% (range 71% shrinkage, 22% increase); median percentage of residual viable tumor cells was 26% (range, 10%–90%). Patients receiving 20% of TV demonstrated pathologic complete responses. Seven grade 3 adverse events occurred, which were reversible. Conclusions: A single intratumoral injection of NBTXR3 at 10% of TV with preoperative EBRT was technically feasible with manageable toxicity; clinical activity was observed. Clin Cancer Res; 23(4); 908–17. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hafnium oxide nanoparticles (NBTXR3/Hensify) represent the most advanced example, demonstrating clinical efficacy in combination with radiotherapy and obtaining regulatory approval for locally advanced soft tissue sarcoma, with ongoing evaluation in additional tumor types [112,113,114,115].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [112]
In the citing paper
“One important reason is that NBTXR3 has been successfully developed for tumors amenable to direct intratumoral administration, whereas breast cancer is frequently treated following surgical resection or within multimodal treatment pathways that include systemic therapy, limiting opportunities for local nanoparticle delivery and complicating evaluation of biodistribution within residual microscopic”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [112]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“0) 2 (100)/0 18 (82)/4 (18) Tumor localization, n (%)”
BackgroundCortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742 · cited 1×
“In other cancers (27), pCR could be a surrogate marker of efficacy and possibly of survival (28).”
BackgroundWHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5
Fletcher, C. D. �., Bridge, J., Hogendoorn, P. C. W., & Mertens, F. (2013) · Cited by 3,388
WHO classification of tumours of soft tissue and bone
Fletcher, C. D. �. (2013) · Cited by 2,874
O'Sullivan, B., Davis, A. M., Turcotte, R., Bell, R., Catton, C., Chabot, P., Wunder, J., Kandel, R., Goddard, K., Sadura, A., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09292-9 · Cited by 1,598 · cited 9×
“Clin Cancer Res; 23(4) February 15, 2017 Clinical Cancer Research 912”
BackgroundInfluentialYang, J. C., Chang, A. E., Baker, A. R., Sindelar, W. F., Danforth, D. N., Topalian, S. L., DeLaney, T., Glatstein, E., Steinberg, S. M., Merino, M. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.197 · Cited by 1,541
ROSENBERG, S. A., TEPPER, J., GLATSTEIN, E., COSTA, J., BAKER, A., BRENNAM, M., DEMOSS, E. V., SEIPP, C., SINDELAR, W. F., SUGARBAKER, P., et al. (1982) · Annals of Surgery · doi:10.1097/00000658-198209000-00009 · Cited by 1,348
Trojani, M., Contesso, G., Coindre, J. M., Rouesse, J., Bui, N. B., De Mascarel, A., Goussot, J. F., David, M., Bonichon, F., & Lagarde, C. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910330108 · Cited by 1,317 · cited 1×
“The tumor types were characterized following theWHO criteria (14) and graded according to the French Federation of Cancer Centers system (15).”
MethodSelf-citationThe big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088 · cited 1×
“Drug delivery systems that change the biodistribution of drugs have been extensively used (10).”
BackgroundPisters, P. W., Harrison, L. B., Leung, D. H., Woodruff, J. M., Casper, E. S., & Brennan, M. F. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.859 · Cited by 1,001
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
“NBTXR3/Hensify enhances external radiotherapy via a physical mode of action that relies on hafnium's natural radioenhancing properties.(14,15) Specifically, the interaction between ionizing radiation and hafnium facilitates a higher energy deposit as compared to ionizing radiation without hafnium interaction; this res…”
BackgroundRethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30326-2 · Cited by 536
Self-citationApplication of Radiosensitizers in Cancer Radiotherapy
Gong, L., Zhang, Y., Liu, C., Zhang, M., & Han, S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s290438 · Cited by 479
“Researchers from France discovered that HfO2 can be used as a radiosensitizer with low cytotoxicity.(186) A Phase I trial (NCT03589339) combining hafnium oxide nanoparticles (NBTXR3) with anti-PD-1 therapy in microsatellite instability-high solid malignant tumour and a Phase I–II clinical trial (NCT02805894) of NBTXR3…”
Background
Metadata
- Authors
- Bonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., Ait Sarkouh, R., Dimitriu, M., Borghi, E., Levy, L., Deutsch, E., & Soria, J.-C.
- Affiliations
- Université Paris Sciences et Lettres (FR)
- 2Gustave Roussy Cancer Campus, Villejuif, France.
- Institut Bergonié (FR)
- Institut Gustave Roussy (FR)
- 4Nanobiotix, Paris, France.
- Nanobiotix (France) (FR)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-02-14
- Volume
- 23
- Issue
- 4
- Pages
- 908-917
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2529570061
- Cited by
- 243
- References
- 33
- Citations by year
- 2026: 26 · 2025: 24 · 2024: 31 · 2023: 23 · 2022: 36 · 2021: 30 · 2020: 26 · 2019: 23 · 2018: 15 · 2017: 9
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- NBTXR3, hafnium oxide nanoparticles, soft tissue sarcoma, locally advanced sarcoma, preoperative radiotherapy, intratumoral injection, dose escalation, recommended dose, pathological complete response, dose-limiting toxicity, injection site pain
- MeSH terms
- Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Female, Hafnium, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Oxides, Preoperative Care, Radiotherapy Dosage, Sarcoma, Neoplasm, Residual, Radiotherapy, Adjuvant, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1297
- The paper
- Bonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., Ait Sarkouh, R., Dimitriu, M., Borghi, E., Levy, L., Deutsch, E., & Soria, J.-C. (2017). First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.